New York: Drugmaker AstraZeneca is now facing tough questions from experts after the company admitted a manufacturing error by a contractor. Earlier this week, the drug manufacturer has announced about the promising results from its Covid-19 vaccine trial After disclosing promising results.
AstraZeneca on Monday had announced that it recorded positive high-level results from an interim analysis of clinical trials of the Covid-19 vaccine candidate in the UK and Brazil. The results showed its vaccine was highly effective in preventing the disease, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.
The error came to light after AstraZeneca, which is developing the potential Covid-19 vaccine in partnership with Oxford University, revealed different efficacy results from two different dose regimes.
In the two different dose regimens vaccine efficacy was 90 per cent in one and 62 per cent in the other.